Otsuka Tomoyuki

オオツカトモユキ | Otsuka Tomoyuki

Affiliation and department：
Research theme for competitive and other funds (2)：

2015 - 2018 Analysis of immune response against cancer, which may lead to establishment of WT1 peptide-based immunotherapy for the conventional treatment-resistant malignancies in the respiratory medicine field
2012 - 2015 Development of WT1 peptide-based immunotherapy for inoperable thoracic malignant tumors, and analysis of immunodynamics of the novel therapy

Papers (37)：

Yukinori Takenaka, Takemoto N, Otsuka T, Nishio M, Tanida M, Fujii T, Hayashi K, Suzuki M, Mori M, Yamamoto Y, et al. Validation and comparison of prognostic scoring systems in patients with head and neck squamous cell carcinoma treated with nivolumab. Japanese journal of clinical oncology. 2024
Nao Yamamoto Nishimura, Kengo Aoki, Shihoko Koyama, Minako Nishio, Tomoyuki Otsuka, Masayoshi Miyazaki, Tadashi Yoshii, Shinji Otozai, Junji Miyabe, Mizuki Korematsu, et al. The impact of COVID-19 pandemic on head and neck cancer diagnosis and treatment. Journal of Dental Sciences. 2023
Yasunobu Ishizuka, Takeshi Omori, Naoki Shinno, Masaaki Yamamoto, Hisashi Hara, Tomoyuki Otsuka, Minako Nishio, Naohiro Nishida, Fumie Fujisawa, Naotoshi Sugimoto, et al. Early detection of brain metastases and appropriate local therapy followed by systemic chemotherapy may improve the prognosis of gastric cancer. Scientific reports. 2023. 13. 1. 20805-20805
Otsuka T, Hashii Y, Murayama S, Ishizuka Y, Kojitani Y, Nishio M, Kudo T. Checkpoint inhibitor-induced gastritis followed by delayed severe hepatitis in a patient with lung metastases of head and neck squamous cell carcinoma: a case report. Frontiers in oncology. 2023
Yukio Kadokawa, Satoko Inoue, Akitoshi Tatsumi, Mayako Uchida, Keiko Fujita, Mari Takagi, Takako Inoue, Shuichi Ohe, Yasutomo Nakai, Tomoyuki Otsuka, et al. Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective study. JGH open : an open access journal of gastroenterology and hepatology. 2023. 7. 2. 87-97

ｍore...

MISC (34)：

西村奈穂, 青木健剛, 小山史穂子, 西尾美奈子, 大塚倫之, 宮崎正義, 喜井正士, 音在信治, 北村公二, 宮部淳二, et al. COVID-19の流行が頭頸部がんの診断と治療に与える影響について. 日本癌治療学会学術集会抄録集. 2022. 60回. P61-4
久野育美, 大塚倫之, 杉本直俊, 角田紗保里, 邨田裕子, 渡辺正洋, 前田通秀, 中川美生, 久毅, 太田行信, et al. 婦人科がんにおけるMSI検査の結果とMSI-H症例でのpembrolizumab投与について. 日本婦人科腫瘍学会雑誌. 2021. 39. 1. 314-314
大塚倫之, 清水康, 花井信広, 假谷伸, 安松隆治, 横田知哉, 塚原清彰, 安藤瑞生, 羽生健司, 上田勉, et al. 実臨床下での頭頸部癌患者に対するニボルマブの有効性と安全性、2年フォローアップ. 日本癌治療学会学術集会抄録集. 2020. 58回. O1-3
西村潤一, 長谷川晶子, 工藤敏啓, 大塚倫之, 安井昌義, 原口直紹, 牛込創, 山田大作, 杉村啓二郎, 山本和義, et al. 大腸癌に対するオキサリプラチン化学療法のCINVに対するオランザピンの安全性. 日本癌治療学会学術集会抄録集. 2019. 57回. P77-3
大塚倫之, 西田純幸, 濱口眞成, 柴原理志, 白山敬之, 川合祥子, 木村恵子, 平田陽彦, 木田博, 石井健, et al. 進行肺癌に対するCpG ODN(K3)皮下注射による自然免疫の活性化(Activation of innate immunity in patients with advanced lung cancer following subcutaneous injection of CpG ODN(K3)). 日本がん免疫学会総会プログラム・抄録集. 2019. 23回. 169-169

ｍore...

Professional career (1)：

Doctor of Medicine (Osaka University)

Awards (1)：

2023/12 - 大阪大学医学部附属病院令和5年度大阪大学医学部附属病院病院長表彰論文賞選考論文奨励賞 CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page